QNTM — Quantum Biopharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1771885 ·
Ontario, Canada
Last close
$3.85
Market Cap
$24.75M
52W High
$19.30
52W Low
$2.07
ADV30
229,603
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,281,086 | -3,252,967 | 14,391,885 | 3,647,072 | 8,297,670 |
| Mar 2026 | 0 | — | -2,909,492 | -13,560,299 | 14,926,075 | 4,341,908 | 16,345,974 |
| Dec 2025 | 0 | — | -2,359,801 | -3,026,467 | 11,160,909 | 1,905,357 | 6,058,294 |
| Sep 2025 | 0 | — | -4,658,195 | -5,319,029 | 14,153,228 | 445,944 | 6,646,480 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,644,918
Investing CF
$-3,495,520
Financing CF
$9,964,033
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-11.07
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-211,846,469
Inventory
$51,468
Receivables
$208,524
ST Investments
$222,906
EBIT TTM
$-31,657,316
Pretax Income TTM
$-31,970,523
Interest Exp TTM
$313,207
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,317,409 | -26,175,286 | 11,160,909 | 6,058,294 | 6,924,475 | -8,237,012 |
| Dec 2024 | 0 | -15,884,034 | -14,202,724 | 17,119,224 | 6,678,992 | 11,480,538 | -6,876,479 |
| Dec 2023 | 0 | -19,570,114 | -17,902,179 | 17,474,828 | 4,565,566 | 13,236,763 | -10,827,264 |
| Dec 2022 | 0 | -27,429,611 | -23,606,828 | 38,410,656 | 7,868,436 | 30,542,220 | -28,333,273 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-7.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AYTU | AYTU BIOPHARMA, INC | $24.78M | $2.28 | — |
| VICP | Vicapsys Life Sciences, Inc. | $25.41M | $0.79 | — |
| RADX | Radiopharm Theranostics Ltd | $23.86M | $1.65 | — |
| UPC | Universe Pharmaceuticals INC | $23.79M | $4.75 | — |
| TXMD | TherapeuticsMD, Inc. | $23.73M | $2.05 | — |
News headlines (Yahoo Finance, 1h cache)
Quantum BioPharma (QNTM) Receives FDA Green Light to Move Lucid-MS Into Phase 2 Testing
2026-09-25 19:00 · Yahoo
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
2026-09-24 12:00 · Yahoo
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
2026-09-17 12:00 · Yahoo
Quantum BioPharma (QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
2026-09-15 19:30 · Yahoo
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
2026-09-15 12:00 · Yahoo
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
2026-09-11 12:30 · Yahoo
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
2026-09-09 12:30 · Yahoo
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
2026-09-01 23:00 · Yahoo
Quantum Biopharma Provides Corporate Update
2026-08-21 23:00 · Yahoo
Quantum BioPharma (QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
2026-08-20 18:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.